ADPT Long Call Strategy
ADPT (Adaptive Biotechnologies Corporation), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Adaptive Biotechnologies Corporation, founded in 2009 and headquartered in Seattle, Washington (operating as Adaptive TCR Corporation until its name change in December 2011), is a commercial-stage entity focused on pioneering an immune medicine platform. This advanced platform is engineered for the precise diagnosis and effective treatment of a broad spectrum of illnesses. The company offers several core technological solutions. Its immunoSEQ platform, a foundational immunosequencing product, is vital for translational research and discovering novel prognostic and diagnostic markers. For confirming past COVID-19 infections, Adaptive provides T-Detect COVID. Additionally, clonoSEQ functions as a critical clinical diagnostic tool, enabling the detection and continuous monitoring of minimal residual disease in individuals with multiple myeloma, B-cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia; it is also available as a CLIA-validated laboratory-developed test for other lymphoid cancers.
ADPT (Adaptive Biotechnologies Corporation) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $3.35B, a beta of 2.15 versus the broader market, a 52-week range of 9.955-21.005, average daily share volume of 2.4M, a public-listing history dating back to 2019, approximately 619 full-time employees. These structural characteristics shape how ADPT stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 2.15 indicates ADPT has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a long call on ADPT?
A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.
Current ADPT snapshot
As of June 30, 2026, spot at $21.25, ATM IV 86.40%, IV rank 15.24%, expected move 24.77%. The long call on ADPT below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 17-day expiry.
Why this long call structure on ADPT specifically: ADPT IV at 86.40% is on the cheap side of its 1-year range, which favors premium-buying structures like a ADPT long call, with a market-implied 1-standard-deviation move of approximately 24.77% (roughly $5.26 on the underlying). The 17-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated ADPT expiries trade a higher absolute premium for lower per-day decay. Position sizing on ADPT should anchor to the underlying notional of $21.25 per share and to the trader's directional view on ADPT stock.
ADPT long call setup
The ADPT long call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With ADPT near $21.25, the first option leg uses a $21.25 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed ADPT chain at a 17-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 ADPT shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $21.25 | N/A |
ADPT long call risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.
ADPT long call payoff curve
Modeled P&L at expiration across a range of underlying prices for the long call on ADPT. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use long call on ADPT
Long calls on ADPT express a bullish thesis with defined risk; traders use them ahead of ADPT catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
ADPT thesis for this long call
The market-implied 1-standard-deviation range for ADPT extends from approximately $15.99 on the downside to $26.51 on the upside. A ADPT long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current ADPT IV rank near 15.24% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on ADPT at 86.40%. As a Healthcare name, ADPT options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to ADPT-specific events.
ADPT long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. ADPT positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move ADPT alongside the broader basket even when ADPT-specific fundamentals are unchanged. Long-premium structures like a long call on ADPT are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current ADPT chain quotes before placing a trade.
Frequently asked questions
- What is a long call on ADPT?
- A long call on ADPT is the long call strategy applied to ADPT (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With ADPT stock trading near $21.25, the strikes shown on this page are snapped to the nearest listed ADPT chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are ADPT long call max profit and max loss calculated?
- Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the ADPT long call priced from the end-of-day chain at a 30-day expiry (ATM IV 86.40%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a ADPT long call?
- The breakeven for the ADPT long call priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current ADPT market-implied 1-standard-deviation expected move is approximately 24.77%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a long call on ADPT?
- Long calls on ADPT express a bullish thesis with defined risk; traders use them ahead of ADPT catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
- How does current ADPT implied volatility affect this long call?
- ADPT ATM IV is at 86.40% with IV rank near 15.24%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.